NCT06736587

A Randomized, Double-blind, Placebo-controlled, Dose-escalation Phase 1 Clinical Tiral in Healthy Male Volunteers

A Randomized, Double-blind, Placebo-controlled, Single and Multiple Dose, Dose-escalation Phase 1 Clinical Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DWP212525 in Healthy Male Volunteers

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 76 (estimated)
• Sponsor: Daewoong Pharmaceutical Co. LTD. · Industry
• Sex: Male
• Age: 19 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The safety and tolerability of single and multiple administration of DWP212525

Detailed description

The safety and tolerability of single and multiple administration of DWP212525 will be evaluated in healthy adult male volunteers.

Conditions

• Autoimmune Diseases

Interventions

Type	Name	Description
DRUG	DWP212525 10mg	DWP212525 10mg
DRUG	DWP212525 30mg	DWP212525 30mg
DRUG	DWP212525 50mg	DWP212525 50mg
DRUG	DWP212525 100mg	DWP212525 100mg
DRUG	DWP212525 200mg	DWP212525 200mg
DRUG	DWP212525 400mg	DWP212525 400mg
DRUG	DWP212525 placebo	DWP212525 placebo

Timeline

• Start date: 2024-12-10
• Primary completion: 2026-06-30
• Completion: 2026-06-30
• First posted: 2024-12-16
• Last updated: 2024-12-18

Locations

1 site across 1 country: South Korea